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ABSTRACT 
 
Objective: National medicines policies (NMPs) provide a means for governments to achieve their 
objectives in relation to pharmaceuticals and other medicines. This research aimed to identify 
challenges to implementing the objectives of the Australian NMP from the perspective of key 
stakeholders. 
Methods: In 2012 and 2103, we conducted 30 semi-structured interviews with stakeholders involved 
in the discovery, clinical testing, regulation and funding of medicines in Australia. We asked 
participants to describe their careers and to give their opinions on specific issues surrounding drug 
development, clinical research, regulation and subsidisation in Australia. Data were analysed using 
Morse’s outline of the cognitive basis of qualitative research and Charmaz’s outline of data analysis 
in grounded theory. The initial phase of “open coding”, revealed findings that could be mapped to 
three of the four objectives of the NMP. We then conducted “focused coding” for themes relevant 
to these objectives. 
Results: Participants identified many issues relevant to the ongoing evolution of the NMP, relating 
primarily to ongoing tensions between the commercial objective of ensuring a viable medicines 
industry, and the non-commercial objectives of ensuring that medicines are safe, effective and 
affordable. There were also a number of other challenges identified to the achievement of both the 
commercial and non-commercial objectives of the NMP. These included limits to government 
funding, globalisation, consumer advocacy, changing scientific paradigms and new information 
technologies. 
Conclusions: There are many issues that need to be addressed if policymakers are to achieve the 
best outcomes from the NMP. Tensions between the commercial and non-commercial objectives of 
the NMP suggest the need to ensure that one stakeholder group’s imperatives do not stifle those of 
other groups. At the same time, there are a number of emerging issues that are likely to concern all 
stakeholders equally, and these are both challenges and opportunities for new kinds of 
collaboration. 
KEY QUESTIONS 
1. What is known about the topic? 
We know that stakeholders have a number of concerns about medicines policy, but little is known 
about the specific challenges to implementing medicines policy from the perspective of those 
involved.  
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2. What does this paper add? 
We demonstrate that stakeholders have many concerns that could impact upon the implementation 
of medicines policies. These relate primarily to ongoing tensions between the objective of ensuring a 
viable medicines industry, and the objectives of ensuring that medicines are safe, effective and 
affordable.  There are also a number of issues that potentially pose a challenge to achieving both 
commercial and non-commercial objectives of the NMP. These include limits to government funding, 
globalisation, consumer advocacy, changing scientific paradigms and new information technologies. 
3. What are the implications for practitioners? 
Policymakers need to systematically address the barriers to the ongoing implementation of the 
NMP. Policymakers should also ensure that one imperative (such as the commercial imperative) 
does not stifle other objectives. Other emerging issues are likely to concern all stakeholders, and 
these provide opportunities for new kinds of collaboration among stakeholders.  
INTRODUCTION 
National medicines policies are expressions of governments’ medium and long-term goals in relation 
to the development, testing, regulation, subsidisation and quality use of medicines. 1, 2 Australia was 
one of the first industrialised nations to formulate a national medicines policy in the mid-1990s. In 
2000, the Commonwealth Government of Australia gazetted its “National Medicines Policy” (NMP), 
aimed at “meet(ing) medication and related service needs, so that both optimal health outcomes 
and economic objectives are achieved.”3 The NMP does not provide specific technical direction, but 
rather offers  ‘frameworks for action’ that balance divergent interests among stakeholders, most 
notably those between governments and manufacturers.4, 5 
Australia’s NMP has four central objectives: 1) medicines should meet appropriate standards of 
quality, safety and efficacy (mostly the responsibility of the Therapeutic Goods Administration-TGA); 
2) timely access to the medicines that Australians need, at a cost that individuals and the community 
can afford (mostly through the Pharmaceutical Benefits Scheme); 3) quality use of medicines 
(through, for example, the National Prescribing Service) and 4) maintaining a responsible and viable 
medicines industry.3 The NMP specifies how each of these objectives should be achieved, and which 
stakeholder groups have primary responsibility for ensuring success.  
The NMP recognises that all four of its objectives are interdependent and must be pursued in an 
integrated way. The NMP also emphasises the importance of “partnerships”, and of ensuring that all 
stakeholders are accounted for in pursuit of the objectives of the NMP so that the interests of one 
stakeholder group does not come to dominate medicines policymaking. The NMP doesn't aim to 
finally resolve the inherent tensions among stakeholder objectives but rather to provide each 
stakeholder group with a 'reference point for lobbying'6 and a means to manage tensions and avoid 
any one objective being pursued to the exclusion or detriment of the others.7 
Since the inception of the NMP, it has formed the conceptual basis for a number of substantial 
developments in policy and regulation aimed at improving the registration, post-market surveillance, 
promotion, prescribing and use of medicines, as well as promoting system sustainability.   Numerous 
working groups and forums, comprising government, manufacturer, medical, pharmacy and 
consumer representatives, have been formed to tackle these policy issues. 5, 7-10 
While Australia’s NMP has come to be regarded as an exemplary model of coordinating stakeholders 
towards shared objectives,7 policymaking processes have frequently involved contest, negotiation 
and compromise among the NMP’s ‘partners’. Reforms in drug pricing and listing, for example, have 
directly pitted the government’s necessary focus on cost-containment against industry’s imperative 
of getting the highest price it can for its products. These reforms include the F1/F2 formulary split 
that distinguishes between newer patented medicines and older generics, and the accelerated price 
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disclosure requirements that allow the Government to save money from the discounting 
arrangements between pharmacists and wholesalers for generic medicines.11, 12  
Given how contested medicines policymaking can be, it is essential to know what might be the 
barriers to the implementation and evolution of these policies from the perspective of the 
stakeholders involved.  We are not aware of any work that has focused explicitly on this question in 
Australia, with the exception of one qualitative study that we conducted, in which we explored the 
engagement of the Australian pharmaceutical industry with the concept of quality use of medicines 
(QUM).13 p314 This research demonstrated that, while employees of pharmaceutical companies 
claimed that they were committed to QUM and had a good understanding of the concept, QUM did 
not seem to have brought about structural changes to industry. Nor was QUM positioned as the 
central goal or framework in designing a company’s operational strategies. Moreover, participants 
expressed a significant degree of ambivalence towards governments and medical organisations. 
These findings were interpreted to mean that uptake of QUM by the pharmaceutical industry is far 
from perfect and that its implementation is “infused with issues of power and vulnerability; trust 
and mistrust; altruism, self-interest and coercion.”13 p319 
While there is still much work to be done in relation to QUM, of the four NMP objectives, it is the 
most developed and has had the greatest resources devoted to it. There is a “National Strategy for 
Quality Use of Medicines”14 and the National Prescribing Service has been heavily invested since its 
inception in the late 1990’s in a “partnership approach”, involving “health professionals, consumers, 
the Government and the pharmaceutical industry coming together to solve problems” relating to 
quality use of medicines.15 p31 Far less systematic attention has been paid to the three other 
objectives of the NMP.  
In 2012 and 2013, we conducted research aimed at exploring drug development, clinical research 
and the regulation and funding of medicines from the perspective of all key stakeholders. In this 
article, we present the results of this study that pertain to the implementation of the National 
Medicines Policy. 
METHODS 
We chose a qualitative approach to eliciting stakeholders’ perspectives because we wanted to 
explore issues in depth, and allow our participants to spontaneously raise issues that they thought 
were important—both so that no major themes would be missed, and so that the issues of greatest 
salience to stakeholders could be identified. We conducted 30 face-to-face interviews in late 2012 
and early 2013.  This is a typical number of interviews for an in-depth qualitative study, which aims 
for depth, variation and thematic saturation rather than generalisability.16  
Sampling was purposive. To ensure that our research encompassed all phases of drug development, 
we conducted interviews with stakeholders involved in basic science research, clinical research, 
medicines regulation and funding, as well as with consumer representatives. We sought the views of 
those working in the pharmaceutical industry and in universities, research institutes and government 
regulatory and funding agencies. Industry participants came from a variety of professional 
backgrounds, particularly academic research, clinical medicine, and pharmacy. They held a variety of 
positions in the pharmaceutical industry as medical directors, clinical research managers, regulatory 
affairs managers and pricing and reimbursement managers.  
Interviewees were identified first through organizational websites and the professional contacts of 
the research team and then via snowball sampling from the initial group. 33 people were 
approached in total and 3 declined to be interviewed (one industry employee, one academic basic 
scientist and one regulator). All participants signed consent forms and agreed to speak from their 
own (rather than their organisation’s) perspective. 
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Semi-structured interviews lasting one to two hours were conducted by one of the research team. 
Participants were first asked to describe, in their own words, their career trajectories and 
experiences. They were asked how they came to work in their current positions, how they learned to 
fulfil their current roles and responsibilities, and about the influence of any role models. They were 
asked to describe people they admired and people of whom they disapproved and to discuss those 
aspects of their work they found most and least rewarding. They were then asked for their opinions 
on specific issues surrounding drug development, clinical research, regulation and drug subsidisation 
in Australia, such as the globalization of clinical research, the current regulatory and economic 
environment, and relationships between industry and academia.  
Interviews were recorded and transcribed verbatim. For data analysis, we drew both on Morse’s 
outline of the cognitive basis of qualitative research17 and on Charmaz’s outline of data analysis in 
grounded theory.16 This procedure involved initial coding for themes, and synthesizing themes into 
analytic categories.  Coding was conducted independently by three researchers, and agreement was 
reached on the major themes and analytic categories. Thematic saturation—i.e. the point at which 
no new themes were emerging—was reached after approximately fifteen interviews. 
We emphasise that, because we wanted to allow issues to arise spontaneously, interviews were 
loosely structured and did not focus explicitly on issues to do with the NMP. The initial phase of 
“open coding” revealed findings that could be mapped to three objectives of the NMP:  1) medicines 
should meet appropriate standards of quality, safety and efficacy; 2) timely access to the medicines 
that Australians need, at a cost that individuals and the community can afford; and 3) maintaining a 
responsible and viable medicines industry. We then conducted “focused coding” in order to extract 
further themes relevant to these three NMP objectives. At this point it became clear that the issues 
we had identified could be divided into two broad analytic categories: 1) issues reflecting tensions 
between the commercial and non-commercial objectives of the NMP, and 2) issues potentially 
impacting upon all objectives of the NMP.  
Because interviews were semi-structured and numbers representing each sub-group were small, we 
did not attempt to draw fine distinctions among subgroups. We therefore note in our results where 
obvious differences in opinion were evident between stakeholder groups (e.g. between industry and 
non-industry participants) but we do not focus on these distinctions or make any claims about their 
generalisability. 
The study was approved by the university’s research ethics committee. 
RESULTS 
Two key analytic categories arose from the data. The first was that there remains a significant 
amount of perceived tension between the objective of ensuring a viable medicines industry and the 
objectives of ensuring that medicines are safe, effective, accessible and affordable—i.e. between the 
commercial and non-commercial goals of the NMP. The second was that there is a set of emergent 
challenges to drug development that are of significance to the achievement of both commercial and 
non-commercial objectives of the NMP.  
Ongoing tensions between objectives of the NMP 
The most obvious tension to arise from our data was that between the objective of ensuring a viable 
medicines industry and the objectives focused on safe, effective, accessible and affordable 
medicines.  
There was a view among some participants that relationships between industry and other 
stakeholders are improving, and some industry participants were of the view that even the most 
commercially-oriented industry activities are supportive of the “public health” objectives of the NMP 
such as promoting the development of high quality, safe and effective medicines. 
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P10 (Industry clinical and regulatory affairs manager): It was just too difficult a drug to leave on the market as a 
[disease] drug, when GPs would be managing it … and the company chose to pull it off the market pretty soon 
after its launch, and I think that was a good call. 
Most participants (from both inside and outside industry), however, were less sure about the 
compatibility of the objective of supporting the pharmaceutical industry and the other objectives of 
the NMP. This, in turn, was seen by participants to stem mostly from lack of commitment on the part 
of industry employees to the goals of public health. 
Promoting commerce vs. developing high quality, safe and effective medicines 
With respect to the objective of developing high quality, safe and effective medicines, several (non-
industry) participants argued that, while industry was generally compliant with registration 
requirements, it was not sufficiently committed to post-registration “pharmacovigilance” and post-
marketing research.  
P22 (Academic researcher/clinical pharmacologist): it’s almost like you’ve got to drag them kicking and screaming 
… you’ve actually got to track them down and see if [a promised surveillance activity] occurred.  
Promoting commerce vs. ensuring access to affordable medicines 
With respect to ensuring access to affordable medicines, a number of participants expressed concern 
about the price that the pharmaceutical industry demands for its medicines. Frustration was also 
expressed about the perceived unwillingness of the industry to see itself as part of a broader social 
and economic system of health care, which has no option but to consider opportunity costs. 
P16 (Government payer): I get … frustrated with industry, who says you’re not doing this, and you’re not doing 
that, and we say well guys what do you want us to do?  Do you want us to close hospitals so we can pay for you?  
Importantly, even some industry participants acknowledged that industry is not always fully 
committed to, or able to commit fully to, making their medicines affordable.  
P12 (Industry medical director): The most frustrating thing for me personally is I think industry is becoming far 
too fixated on making money, and losing sight of what we are really here to do [which] is to provide innovative, 
high-quality, affordable medicines. 
P14 (Industry pricing/reimbursement manager): We’re focusing on a narrow, narrow population; to generate the 
return on a narrow population you have to multiply the price, it’s a hard reality. And the same hard reality is that 
individuals can’t afford that.  
Challenges to promoting a viable medicines industry 
While participants focused mostly on the ways in which the pharmaceutical industry might thwart 
other (non-commercial) objectives of the NMP, there was also some talk about how these other 
aspects of the NMP might thwart the objective of promoting a viable medicines industry. Concern 
was expressed, for example, by both industry and non-industry participants about the TGA and the 
PBAC demanding ever-more data from those conducting trials, thus placing undue pressure on 
pharmaceutical companies conducting trials. 
P20 (Academic clinical researcher): The whole system of governance … It’s now being taken over by people 
clearly with OCD, who’ve got no insight at all.   It’s just preposterous.  And it’s killing the whole game.   
Concern was also expressed by both industry and non-industry participants about pricing reforms 
that might make companies less willing to invest in clinical research in Australia because they are 
unlikely to get a return on investment.  
P14 (Industry pricing and reimbursement manager): We must justify a commercial return commensurate with 
the rest of our industry, with our past performance, and with other industries as well.  And that will determine 
where we channel our research, and that’s where the payer question comes into it, which is if the commercial 
return on the investment is not within what our expectations with our risk of return ratio would be, then we 
would have to channel it elsewhere.   
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Other tensions 
In addition to tensions between commerce and public health, concern was also expressed about the 
tendency of the TGA to have a restrictive view about which clinical benefits are worthwhile, thus 
inappropriately preventing some useful medicines from entering or staying on the market.  In this 
way, the objective of promoting the development of high quality, safe and effective medicines was 
seen to be in tension with the objective of ensuring access to medicines. 
P25 [Academic clinical researcher]: [The regulators] seem to tend to focus on some aspect that they think is 
important, and be fairly closed minded about other potential benefits.  So for instance when the newer insulins 
came in they seemed to be only willing to recognise the benefit of reducing blood sugar levels, in other words 
HbA1c, and to not be willing to recognise the benefit of reducing risk of hypoglycaemia, which as far as diabetic 
patients and physicians are concerns is extremely important. 
Emergent challenges of relevance to both commercial and non-commercial objectives of the NMP 
All participants, no matter what their role, spoke at length about a number of broader social, 
political, economic and scientific forces, including increasing limitations of government funding for 
biomedical research and development, globalisation, consumer advocacy, changing scientific 
paradigms, and new information technologies. These were seen to have the potential to slow 
down—if not derail—achievement of both commercial and non-commercial objectives of the NMP. 
Lack of government funding for drug development and policymaking 
All participants complained about what they perceived to be inadequate government support for the 
objectives of the NMP (as well as for their own activities).  
 Challenges to developing high quality, safe and effective medicines 
With respect to promoting the development of high quality, safe and effective medicines, concern 
was expressed about the reliance of the TGA on commercial funding. While some participants (both 
within and outside industry) saw it as an advantage for the TGA to be funded by industry and thus 
independent of government and not reliant on public service funding, others (primarily from outside 
industry) were concerned about the effects of industry funding on the TGA’s independence and 
ability to carry out their tasks thoroughly. 
P19 [Consumer]: Our post-medicine marketing and our post-device marketing results are not being fed into the 
system quickly enough for consumers to be protected quickly enough … I think there’s been some commitment 
to try and improve that, but I don’t, it hasn’t happened to my knowledge yet. 
Both industry and non-industry participants also observed that government funding priorities and 
political manoeuvring could have a profound impact on the capacity of both academic and industry-
supported researchers to conduct post-marketing research and surveillance.  
P22 [Academic researcher/clinical pharmacologist]: There are a ton of people who are interested in adverse drug 
reactions, that would move into that area if money was put in that area, but there’s just next to no money goes 
into that area … It’s a major source of morbidity and mortality in Australia … and yet politicians come up with a 
kind of ‘oh people need to be educated more about drugs’ or some such thing, before they prescribe them.  And 
you go ‘oh good, all 10,000 of them?’  
 Challenges to ensuring access to affordable medicines 
With respect to ensuring access to affordable medicines, several industry participants—argued that 
the government does not commit enough money to the funding of medicines relative to other 
societal goods.  
P9 (Health economist working in industry): I always like to go back to the banks – the Commonwealth Bank made 
$10billion worth of profit last year.  We spent $8 billion on drugs for the whole country … We forget to put stuff 
back into perspective.   
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A related concern—expressed by those inside and outside industry—was that equity of access to 
medicines—particularly medicines used to treat rare diseases or subsets of diseases—could be 
threatened by the PBAC’s mandate to ensure cost-effectiveness at a population level. 
P22 [Academic clinical researcher/clinical pharmacologist]: so I chaired the (hospital medicines committee) and 
the most common bit of work we had was, ‘we’ve got a person with unusual disease for which there’s no good 
quality studies, we want to use this drug which seems logical…and we want to use something that has a 
mechanism of action that seems to make sense, can the drug committee pay for it, or will the hospital pay for it?’  
And it was all because the pharmaceutical benefits scheme would not, because you know, unless there was this 
pharmaco-economic analysis, and of course that meant that funding was only provided for common diseases.   
 Challenges to promoting a viable medicines industry 
Lack of government investment in the pharmaceutical industry was seen to be a major threat to the 
objective of facilitating a viable medicines industry in Australia. Many participants believed that 
Australia does not invest in its pharmaceutical industry nearly as much as other countries do.  
P6 (Industry pricing and reimbursement manager): The pharmaceutical industry in Australia doesn’t get the same 
government support as it does in Switzerland or the UK, because we haven’t really got much home-grown 
industry… So you will find in a lot of countries overseas that actually have R&D based pharmaceutical companies, 
they treat them better than they do in Australia in terms of government support. 
Lack of government funding was also seen to be a threat to academic basic science and clinical 
research. A number of basic scientists felt that there were insufficient funding schemes to help them 
move the molecules they discover into the early stages of drug development, and to support 
investigator-driven clinical research.  (This was coupled with what was perceived to be extreme risk 
aversion on the part of industry and reluctance on the part of industry—despite rhetoric to the 
contrary—to form genuine public-private partnerships).  
P17 [Academic basic scientist): a big issue for us was how does the NH&MRC fund that gap between this research 
discovery and where industry really comes in, development grants and things like that …Everyone talks about the 
gap, because the gap is real, and the gap is a challenge.  
Globalisation of drug development 
Another issue raised by many participants—both inside and outside industry—was the trend of 
pharmaceutical companies towards conducting most, if not all, of their clinical trials in emerging 
economies/developing countries.  
 Challenges to developing high quality, safe and effective medicines 
Globalisation of clinical research was seen by both industry and non-industry participants to have 
both positive and negative effects on the capacity to promote the development of high quality, safe 
and effective  medicines: On the one hand, the increasingly globalised nature of clinical research was 
seen to have stimulated efforts towards regulatory harmonisation, while on the other it was noted 
to have posed major challenges for regulators who needed to determine whether data derived from 
elsewhere is generalisable to the local population.  
P22 [Academic researcher/clinical pharmacologist]: So the globalisation sort of thing whereby you decide to 
study diabetes and you look at India and you think there’s a few hundred million diabetics, that’s a good place to 
do a study, that’s where the ethics I think become a bit interesting.  And also the science whereby you say well 
that is a population prone to diabetes, what does it mean for our non-Indian, non South Asian based ethnic 
groups? 
 Challenges to ensuring access to affordable medicines 
With respect to ensuring access to affordable medicines, concern was expressed by both industry 
and non-industry participants that if Australia lost its involvement in clinical research, then its 
clinicians would have less access to innovative medicines that can only be accessed through clinical 
trials.  
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P29 [Regulator]: I think it will be very important in the future, because I think we’ll have a whole lot of specialists 
who have never had any experience of using new medicines as they come to market; we won’t have clinical trials 
happening here, which means we won’t have access to medicines. 
 Challenges to promoting a viable medicines industry 
Perhaps most obviously, both industry and non-industry participants argued that the globalisation of 
clinical research was a threat to the objective of promoting a viable medicines industry in Australia, 
because companies would no longer invest in Australian trials. Our participants’ attributed this shift 
of trials out of Australia to the relative ease (and improving quality) of clinical research in emerging 
economies. They compared the system of research oversight in developing countries to that in 
Australia—arguing that the latter has become excessively bureaucratised, expensive and (relatively) 
slow.   
P20 [Academic clinical researcher]: …It’s bad times.  And anybody who claims differently needs to take a very 
good hard long look at what's happening with pharma, because every single pharma company that until four 
years ago had any major capital and resource investment in this country, to be the national or regional 
headquarters of a pretty substantial clinical research and development enterprise, have gone or are going.   
Consumer advocacy 
 Challenges to developing high quality, safe and effective medicines 
Consumers were seen by both industry and non-industry participants to have a role in facilitating the 
development of high quality, safe and effective medicines by, for example, ensuring that labelling 
and product information were ‘consumer-friendly’, and by reporting adverse events. But consumers 
could also sometimes over-react to perceived safety concerns, or be too demanding of information, 
placing unnecessary pressure on the TGA.  
P26 [Regulator]: The experience … with the TGA, is that where if a doctor rang up and said ‘I want to report 
something’, you’d get it done in five minutes – the experience has been that you know, it can take 25 minutes or  
more to deal with a patient. …and also they have expectations of information in return, and whereas you might 
say to a GP ‘look there’s been two cases worldwide and we don’t think it’s really very significant, we’ll keep a 
watch on it’ – you’ve got to spend a long time with a patient.    
 Challenges to ensuring access to affordable medicines 
Similarly, while consumer advocacy for access to affordable medicines was generally viewed 
positively, concerns were expressed, on the one hand, about the degree to which less powerful 
consumer groups were engaged in decisions about resource allocation, and on the other hand the 
perceived unwillingness of more vocal consumers (and their clinicians) to consider opportunity costs 
when advocating for access to particular medicines. 
P16 (Government purchaser/payer): I get frustrated at times with some of the consumer demands, saying ‘we 
want it’ … I remember a taxi driver saying to me once when I was in a taxi a few years ago, saying ‘all the 
government can do is print more money’.  And I said ‘that says it all’.  
Changing scientific paradigms 
 Challenges to developing high quality, safe and effective medicines  
New models of disease and treatment—particularly targeted therapies—were seen by all 
participants to have the potential to improve the effectiveness of medicines for specific sub-groups 
of patients. Many participants, however, (both inside and outside industry) noted that this paradigm 
(sometimes referred to as “personalised medicine”) is yet to fulfil its potential. In particular, there 
was concern that these medicines the imperative to shift to a new paradigm might lead to the 
development of drugs that provide limited or very defined benefit and may not provide a significant 
advance over existing (older) medicines. 
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P10 [Industry clinical and regulatory affairs manager]: I think the era of personalised medicine is fantastic, but 
there needs to be an ongoing commitment to developing a drug throughout its life cycle … by the end of the 20 
year patent life, you’ve got companies going well will I invest that $100 or $200million to do this drug trial in this 
drug which has only got five years left.  And so then what they are doing is they’re trying to come up with a slow-
release formulation, or a slightly different salt, or something that may have less immunogenicity, or something 
like that, and it seems to me that they are investing in a new therapy when there’s still life left in the old one.   
 Challenges to ensuring access to affordable medicines 
New models of disease and treatment—particularly targeted therapies—were seen by all 
participants to have the potential to facilitate access to medicines that would otherwise be deemed 
ineffective because subgroups who benefit would be obscured in large population studies But it was 
also noted that an increased emphasis on targeted therapies could impede equitable and/or 
efficient access to medicines both for those who need them and for the population as a whole. First, 
it was noted that payers currently have difficulty assessing the evidence generated by smaller clinical 
trials, or more complex clinical trials with several study sub-groups. And this in turn might make 
them reluctant to fund some targeted therapies. 
P16 [Regulator]: In some of the cases we don’t have the right methodologies yet … For example the PBAC has 
been trying to engender some debate on indirect comparisons and how do you do cross study comparisons, and 
try and minimise the uncertainty with respect to that.  We’ve got the issue at the moment about with all trials 
with new cancer agents, ethics committees do not allow them to proceed unless they allow the people in the 
placebo arm or the control arm, to switch over to the active arm after a certain period of time.  But we don’t 
know how to manage that data, we don’t know, and again I have a slide which says ‘are we trying to tackle 
tomorrow’s problems with yesterdays’ science’.    
A related concern  (discussed above) was that equity of access to targeted therapies could be 
threatened by the PBAC’s perceived mandate to ensure population-level cost-effectiveness. The 
concern here was that if expensive medicines for rare diseases, or rare subsets of diseases, were 
deemed to be too costly for the population as a whole, then patients with rare diseases would be 
unfairly disadvantaged. 
On the other hand, it was noted that, when targeted therapies are funded, this funding (by 
definition) does not meet the needs of those from other patient subgroups. It also has costs for the 
population as a whole because these medicines (and their companion diagnostics) tend to be very 
expensive.  
P5 [Industry clinical research]: They say it’s quite easy, we’ll just stratify and we’ll develop it in just a sub group of 
people.  But that’s got all the implications then about, because you won’t be able to identify that sub group 
necessarily in your clinical practice … I mean they shouldn’t be getting the therapy if it’s not going to work in 
them, but you’ve spent all the money and you are subsidising therapies for only some patients, which I suppose 
you are helping them.  But it’s a complex societal issue.   
P22 [Academic clinical researcher]: Do you know what the most expensive treatment in… or the most expensive 
item in the treatment of snake bite in Australia is?  It’s not anti-venom, it’s the venom detection kit …  
 Challenges to promoting a viable medicines industry 
The move towards more “targeted” therapies was also seen as a challenge to the objective of 
promoting the viability of the medicines industry, because of the increased complexity of developing 
these medicines.  It was also noted that “data mining” has so far failed to live up to its promise as a 
new approach to drug discovery. 
P29 (Policymaker): The development process for medicines now is so desktop related, there’s all these people 
running programs and lots of matches to find chemicals that maybe will hit targets, but it doesn’t seem to have 
made it any more efficient to actually finding new drugs. 
New information technologies 
 Challenges to developing high quality, safe and effective medicines 
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Finally, while new information technologies, databases and data linkage facilities were seen to be an 
important facilitator of pharmacovigilance and phase 4 studies (and, therefore, the development of 
high quality, safe and effective medicines), many of our participants expressed the view that their 
utility was limited by the unwillingness of government bodies to provide easier access to the 
necessary data.  
P26 (Regulator): The obvious way to do it in Australia is to link the prescribing information and the Medicare 
information with state hospital records and death records, because you can track patients.  And there’s a great 
reluctance to give approvals for that.  There have been a small number of examples, and I just hear conflicting 
stories about attitudes at high levels in the Dept. of Health as to whether they wish to entertain these or not.  
 Challenges to promoting a viable medicines industry 
New information technologies were also seen to facilitate the conduct of complex clinical trials—and 
therefore contribute to the objective of promoting a viable medicines industry.  
P15 [Industry clinical research]: So these days our data capture systems are all electronic, so we can already sit in 
our office here, dial in and see the data coming in from the site.  But now there’s a potential that we could dial 
into the electronic medical record and compare the source data in the patient record with what's in our data 
capture system, which is something we have to do, to ensure the integrity of the data, ensure there is no fraud 
susceptibility to data to health authorities, because they’re going to do that if they come out and do a spot audit.  
So that could have a huge productivity saving, so we don’t have to physically fly to the site each time to do that, 
we can do that on an ongoing basis.   
 
DISCUSSION 
Summary 
Our research makes clear that stakeholders see many challenges to implementing those aspects of 
the NMP focused on 1) medicines meeting appropriate standards of quality, safety and efficacy; 2) 
timely access to the medicines that Australians need, at a cost that individuals and the community 
can afford; and 3) maintaining a responsible and viable medicines industry.  
These challenges fall into two groups: First, there are concerns about tensions between the objective 
of ensuring a viable medicines industry and the objectives of the NMP relating to quality, safety and 
efficacy of medicines, and access to affordable medicines. These concerns stem, from a sense that 
the pharmaceutical industry is insufficiently committed to public health. While some industry 
participants denied that such a tension exists, other industry participants, and all non-industry 
participants, saw significant divergence between the objectives of the pharmaceutical industry and 
those of other stakeholder groups. Second, our participants identified a number of challenges that 
impact upon both commercial and non-commercial objectives of the NMP, including those posed by 
limitations of government funding for biomedical research and development, globalisation, 
consumer advocacy, changing scientific paradigms, and new information technologies.  
Practical implications 
Our findings have a number of implications for those developing and implementing medicines 
policies in Australia. First, by identifying a set of perceived challenges to implementation of the NMP 
from the perspective of all key stakeholders, our findings could provide a useful organising 
framework for those with responsibility for developing and implementing national medicines 
policies.  
Our findings might also be useful in guiding stakeholder collaboration. As mentioned previously, the 
NMP emphasises the importance of “partnerships”, and of ensuring that all stakeholders are 
accounted for in pursuit of the objectives of the NMP. While we did not formally evaluate this aspect 
of the NMP, and cannot say from this research how well stakeholders are working together, we did 
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identify a number of potential threats to stakeholder collaboration, stemming from the perception 
of ongoing tensions between the commercial goals of the pharmaceutical industry and the goals of 
other groups. In this regard it is noteworthy that the most significant reforms in Australian 
pharmaceutical policy to date have focused on the sustainability of the PBS, particularly changes to 
drug pricing arrangements. Reforms such as these have necessarily pitched government’s cost-
containment imperative against industry’s profit imperative, 5, 7 and these unresolved tensions will 
need to be an explicit focus of ongoing policy development. We also identified a number of 
emerging issues that potentially impact upon both commercial and non-commercial objectives of 
the NMP. While these issues pose further challenges for policymakers, they also point to potential 
new opportunities for stakeholder groups to work together as “partners” to manage the external 
forces that affect them all. For example, all stakeholders could coordinate their approaches to 
managing the forces of globalisation. Scientists, regulators and clinicians could work together to 
ensure that targeted therapies are developed efficiently, regulated and funded appropriately, and 
prescribed rationally. And all stakeholders could work together to advocate for the government 
funding they need (rather than pitching their needs against one another’s) within the constraints of 
current government budgets; to develop mechanisms for effective and non-reactionary consumer 
advocacy; and to make the best possible use of emerging information technologies.  
Limitations and future directions 
This was a small qualitative study, so further research is required to determine the generalisability of 
our findings. Further quantitative and qualitative research would also be needed to tease out 
differences among the subgroups we studied. It would be particularly interesting to identify areas of 
convergence and divergence between industry and non-industry groups and between consumers 
and those serving them. Because our method was inductive, we could not know in advance which 
themes would prove to be most significant and might need “unpacking.” Additional studies could 
pursue more targeted questions. Finally, it is possible that many of the stakeholders we interviewed 
may have had concerns about quality use of medicines but, as mentioned previously, this was not 
the focus of our research and we did not attempt to draw out responses that might have related to 
QUM. It is worth noting, however, that  some QUM-related concerns, such as medicines labelling 
and adverse event reporting, did arise in participants’ discussions, which is not surprising given how 
closely QUM is related to the other objectives of the NMP 14 Further research could focus on the 
QUM objective of the NMP. 
CONCLUSION 
Those who are involved in the development, testing, regulation and funding of medicines have a 
number of concerns that could potentially impact upon the ongoing evolution and implementation 
of the NMP.  Policymakers need to be cognisant of these concerns if the NMP is to achieve its 
objectives. With respect to the over-arching principle of the NMP to promote partnerships and 
collaboration, policymakers need to be aware of ongoing tensions, while also recognising emerging 
areas of common concern. These shared concerns can be leveraged as new opportunities for 
stakeholders to unite in the pursuit of common goals. 
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